Emerging Uses for Circulating Tumor Cell Technology
August 21st 2023Detection of circulating tumor cells, which are released from primary or metastatic lesions into the bloodstream and are the “seeds” for distant metastatic lesions, has been of interest in cancer research and treatment because these cells can potentially provide information on cancer detection, prognosis, and likelihood of treatment response with minimally invasive methods.
Read More
Claudin-18.2 Emerges as a Novel Therapeutic Target in GI Malignancies
May 24th 2023CLDN18.2 has become a promising target for the treatment of patients with digestive malignancies, such as gastric cancer, gastroesophageal junction cancer, esophageal cancer, and pancreatic cancer, because of its limited expression in healthy tissues and abnormal overexpression in a range of malignancies.
Read More
Targeting Mesothelin May Yield Results in Hard-to-Treat Solid Tumors
May 22nd 2019Mesothelin, a protein found on cell surfaces and in serum, has emerged as a promising target for immunotherapy-based treatment approaches for several malignancies with poor prognoses and limited treatment options. Investigating novel approaches to optimize delivery and identifying combinations of agents to synergistically improve therapeutic response will be the next steps in bringing mesothelin-targeted therapies into the clinical setting.
Read More
FGFR Alterations Emerge as Enticing Target in Multiple Tumor Types
March 29th 2019Aberrations in fibroblast growth factor receptor (FGFR) signaling are an emerging focus for targeted therapy across multiple types of cancer, particularly urothelial carcinoma, gastric cancer, and intrahepatic cholangiocarcinoma.
Read More
EGFR and ALK Inhibitors in NSCLC Lead to Resistance Challenge
February 13th 2019Treatment strategies moving forward will likely involve development of new targeted TKIs with greater potency and specificity against resistance mutations and different kinase selectivity, sequencing of targeted therapies based on the resistance mutations that develop from prior therapy, and development of combination regimens to target bypass signaling tracks.
Read More
New Strategies Emerge for Urgent Care in Oncology
May 15th 2018The incidence of emergency department visits and subsequent hospitalizations among patients with cancer is relatively common. Cancer-specific urgent care, pathways for symptom management, and more education for patients and healthcare providers are among the approaches that are being implemented to address patients’ needs and manage costs.
Read More
Oncolytic Viruses Primed for Growth
March 15th 2018Amid the rapid expansion of immunotherapy for a wide range of tumor types, oncolytic virus therapies are generating growing attention from researchers and pharmaceutical developers, raising the potential for a new class of immune-enhancing drugs.
Read More
Fresh Look at Gene Fusion Yields Clues in Low-Risk Prostate Cancer
January 10th 2018Although gene fusions between the TMPRSS2 gene and ETS family of transcription factors in prostate cancer have been recognized for more than a decade, the clinical relevance of this fusion event continues to be debated among experts.
Read More
Immunotherapy Combinations Offer Hope in Glioblastoma
October 4th 2017Immunotherapy has shown promise for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor in adults with historically poor prognosis, but experts agree that combination regimens have the greatest potential to achieve durable response.
Read More
Sequencing Strategies Advance Care Amid Challenges in Pancreatic Cancer
July 5th 2017Recent developments in the treatment of metastatic pancreatic cancer have modestly improved outcomes, but reducing morbidities associated with current therapies and developing novel therapeutics will be essential for achieving durable responses and long-term survival.
Read More
HER2+ Breast Cancer Heterogeneity Calls for Combos
May 2nd 2017Targeted therapies have improved outcomes for HER2-positive breast cancer, which is characterized by an aggressive tumor phenotype and lower overall survival. However, questions remain on how to predict which patients will benefit from neoadjuvant or extended HER2-targeted therapies and how to treat patients with triple-positive breast cancer.
Read More
Biomarker-Driven Trials Set Pace in Lung Cancer
August 11th 2016Biomarker-driven trials that include multiple substudies represent a new approach for investigating which patients with lung cancer are more likely to respond to different targeted therapies and are helping to set the pace throughout the oncology field.
Read More